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Summary
Pertussis or whooping cough is typically 
characterised by paroxysms of coughing with a 
whooping sound during inhalation. It is thought 
to be under-diagnosed generally. Whooping 
cough is caused by Bordetella pertussis and 
is highly contagious. Although childhood 
immunisation has been effective in preventing 
the disease, outbreaks in Australia have been 
associated with waning immunity in older 
children and adolescents. The peak incidence 
of infection now occurs in people aged 15 or 
older. When given early in the illness, antibiotics 
can decrease the infectious period, but have no 
effect on the duration or severity of disease. 
Symptomatic treatment of cough has shown no 
clear benefit. Antibiotic prophylaxis of contacts 
is recommended for certain high-risk groups, 
but there is limited evidence of its effectiveness. 
Although infants remain the most at risk for 
severe, life-threatening disease, it is adolescent 
and adult booster immunisation which remains 
critical for prevention programs. 
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Introduction
Pertussis, also known as whooping cough, is a highly 
contagious disease caused by the bacterium Bordetella 
pertussis. It is generally thought to be under-diagnosed and 
remains the least well controlled of all the vaccine preventable 
diseases targeted by the Australian National Immunisation 
Program.1 Epidemics occur every 3–4 years. This is despite 
immunisation continuing to increase, with more than 90% of 
one-year-olds being fully vaccinated. 
The literature suggests that epidemics result from waning 
immunity in later childhood and adolescence. The peak 
incidence of whooping cough in Australia occurs in adolescents 
and adults with more than 70% of pertussis notifications 
occurring in people older than 15 years in 2004–05. Data 
suggest that 10–35% of subacute coughing illnesses in adults 
are due to pertussis infection.2 Death in individuals older than  
10 years of age is rare and non-immunised infants remain 
the most likely group to have severe life-threatening disease 
requiring hospitalisation.1
Clinical presentation
The classic presentation of pertussis is one of spasms of 
coughing with a characteristic inspiratory whoop. However, this 
is less common in older children and adults. The first 1–2 weeks 
of illness with B. pertussis resembles other upper respiratory 
tract infections, with runny nose and mild cough. This is 
followed by the paroxysmal coughing phase in the second and 
third weeks. 
Diagnosis
As classic symptoms of whooping cough do not usually exist 
in adults, exposure to others with prolonged cough is used 
by some as an indicator of pertussis infection. Although less 
frequent in adults, post-tussive vomiting may also indicate 
pertussis. It is therefore important to remember B. pertussis 
when reviewing all adolescents and adults with a chronic cough. 
A number of investigations can be performed to support the 
diagnosis of pertussis. These include:
n	 bacterial culture, polymerase chain reaction (PCR) or 
immunofluorescence assays of nasopharyngeal swab or 
aspirate samples
n	 serological testing to detect rises in immunoglobulin (Ig) A or 
IgG titres to B. pertussis antigens
n	 lymphocyte count (raised counts are a non-specific indicator 
of infection). 
For patients presenting early (within the first three weeks) and 
before the start of antibiotic therapy, PCR, immunofluorescence 
and culture may be useful. For patients who present later, 
serological testing − which is reliant on an immune response − 
is often more helpful.3 Pertussis-specific IgA is only produced 
after natural infection, whereas IgG rises with vaccination 
and natural infection. While a positive IgA test confirms the 
diagnosis of pertussis, a negative result does not exclude the 
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possibility of infection. (It is important to remember that a small 
proportion of the population has an IgA deficiency.) Paired 
samples showing rising titres of specific IgA or IgG are a more 
reliable indication that the patient has pertussis. 
PCR-based testing is the most sensitive and specific of all 
investigations, particularly early in the illness. It is sensitive 
for longer than culture and is less likely to be affected by 
antibiotic treatment (0% detection via culture after seven days 
antibiotics).3 Although direct immunofluorescence is highly 
specific, it has limited sensitivity. Its main advantage is speed. 
Antibiotic treatment 
Antibiotics are recommended in the initial catarrhal phase of 
infection when they are effective in eliminating B. pertussis 
from the nasopharynx and reducing the infectious period. 
However, after three weeks of coughing, antibiotics have no 
measurable effect on reducing the infectious period and are not 
recommended. Patients should avoid contact with susceptible 
individuals until at least five days of antibiotics have been taken.
Table 1 lists the proven antimicrobial therapies in 
nasopharyngeal eradication of B. pertussis. Erythromycin 
has been commonly regarded as the treatment of choice for 
pertussis infections. A 14-day erythromycin course is often 
recommended, although studies have shown similar efficacy 
with a seven-day regimen.4 
The newer macrolides, such as clarithromycin and azithromycin, 
have replaced erythromycin as the standard treatment. 
(However, there is not enough clinical evidence to recommend 
roxithromycin for pertussis infection.) The newer macrolides 
have fewer gastrointestinal adverse effects and reach higher 
concentrations in respiratory secretions. This improved safety 
profile is of particular importance in a therapeutic regimen 
aimed at eradication of organisms rather than improvement 
of symptoms. Studies have shown that patients are more 
compliant when taking the newer macrolides compared with 
erythromycin. Trimethoprim with sulfamethoxazole can be used 
as an alternative to macrolides if necessary, but is not the first 
choice of therapy. 
Symptomatic treatment
A Cochrane review found that some symptomatic treatments for 
the cough associated with pertussis had no clear benefits.5 The 
treatments reviewed included antihistamines, dexamethasone, 
salbutamol and pertussis immunoglobulin. It is possible that 
immunoglobulin offers some improvement in mean number of 
whoops, but further well-designed good quality trials need to be 
developed to determine this.
managing household contacts
B. pertussis is highly contagious and a significant proportion of 
contacts become infected (70–100% of household members). 
The incubation period is typically 7–10 days (range of 4–21 
days). Although there is insufficient evidence that antibiotic 
prophylaxis of close contacts reduces the number of new cases 
or improves clinical symptoms4, it is recommended primarily 
because of the high risks of morbidity and mortality in non-
immunised infants (see box). 
It is suggested that prophylaxis be given as soon as possible, 
but within three weeks of symptom onset in the infected 
contact. The dose and duration of antibiotics for prophylaxis are 
the same as for treatment (see Table 1). 
As three or more injections are required to confer protection, 
infant vaccination is not helpful in controlling a pertussis 
outbreak.1 However, unvaccinated contacts aged eight years or 
older can be offered a diphtheria, tetanus and acellular pertussis 
vaccine and younger contacts can be given a catch-up course. 
Table 1 
effective antibiotic treatment for pertussis 
Drug Adult dose Daily frequency Duration
clarithromycin* 500 mg 
(7.5 mg/kg up to 500 mg)
twice 7 days
erythromycin 250 mg 
(10 mg/kg up to 250 mg) 
four times 7 days
azithromycin*† 10 mg/kg (up to 500 mg) once 3 days
azithromycin* day 1: 500 mg first day 
(10 mg/kg up to 500 mg) 
days 2–5: 250 mg 
(5 mg/kg up to 250 mg) 
once 5 days
trimethoprim with  
  sulfamethoxazole
160 + 800 mg 
(4 + 20 mg/kg up to 160 + 800 mg) 
twice 7 days
* best regimens for microbiological clearance with fewer adverse effects4
† this regimen is documented in a Cochrane systematic review4 although not in Australian antibiotic guidelines6
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Important role of immunisation in adults
Immunisation remains the mainstay of prevention of  
B. pertussis infection. The current Australian immunisation 
schedule1 recommends that a child formulation of a diphtheria, 
tetanus and acellular pertussis vaccine is given at two, four 
and six months of age with a booster at four years. Another 
booster is recommended at 12–17 years of age using the 
adolescent/adult formulation which has a lower concentration 
of pertussis antigens than childhood vaccinations. It is vital to 
remember that adult and adolescent vaccination is an effective 
means of controlling B. pertussis and will have positive health 
ramifications within the community.1 There are no data on the 
duration of immunity following vaccination in teenagers, but 
this is unlikely to be required at intervals less than 10 years. 
A single booster dose is recommended for adults planning a 
pregnancy or for parents of a new infant, preferably before 
hospital discharge. Other household members such as 
grandparents or carers should also be vaccinated. Likewise, 
adults working in health care or childcare should be given a 
booster vaccination. Pertussis booster vaccination can also be 
considered along with a routine diphtheria and tetanus booster 
at age 50.
Conclusion
When B. pertussis is diagnosed early in the illness, antibiotics 
can decrease the infectious period, but have no effect on 
the duration or severity of disease. Antibiotic prophylaxis 
with macrolides, such as clarithromycin and azithromycin, is 
recommended for certain high-risk contacts. Symptomatic 
treatment of cough has not been proven to be significantly 
helpful in decreasing B. pertussis cough. Adolescent and adult 
booster immunisation remains critical for preventing disease 
outbreaks. 
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Self-test questions
The following statements are either true or false  
(answers on page 55)
3. PCR testing is the most sensitive method to detect 
Bordetella pertussis in nasopharyngeal samples.
4. Macrolides are recommended for pertussis infection if the 
patient has had a chronic cough for more than four weeks.
Antibiotic prophylaxis for 'high-risk' contacts of pertussis 
cases 1
n	 Women in their last month of pregnancy, irrespective of 
vaccination status
n	 Members of a household which includes a child less than 
2 years who is not fully vaccinated*
n	 Children and adults who attend a childcare facility where 
children under 2 years are not fully vaccinated 
n	 Healthcare workers and babies (if exposed for >1 hour) in 
a maternity ward or newborn nursery
* Fully vaccinated = three effective doses of pertussis 
vaccine given at least four weeks apart1
Your questions to the PBAC 
Australian Prescriber readers are invited to write in with  
their questions about decisions of the Pharmaceutical 
Benefits Advisory Committee. The segment 'Your questions 
to the PBAC' publishes selected questions from readers, and 
answers from the Committee itself. Questions may address 
issues such as regulatory decisions, pharmaceutical benefits 
listings, withdrawal of a drug from the market and Authority 
prescriptions. Letters and responses may be edited before 
publication.
